NZ629843A - Identification of channelrhodopsin-2 (chop2) mutations and methods of use - Google Patents

Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Info

Publication number
NZ629843A
NZ629843A NZ629843A NZ62984313A NZ629843A NZ 629843 A NZ629843 A NZ 629843A NZ 629843 A NZ629843 A NZ 629843A NZ 62984313 A NZ62984313 A NZ 62984313A NZ 629843 A NZ629843 A NZ 629843A
Authority
NZ
New Zealand
Prior art keywords
chop2
channelrhodopsin
mutations
identification
methods
Prior art date
Application number
NZ629843A
Other languages
English (en)
Inventor
Zhuo-Hua Pan
Original Assignee
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wayne State filed Critical Univ Wayne State
Priority to NZ727041A priority Critical patent/NZ727041B2/en
Publication of NZ629843A publication Critical patent/NZ629843A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/405Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ629843A 2012-03-05 2013-03-05 Identification of channelrhodopsin-2 (chop2) mutations and methods of use NZ629843A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ727041A NZ727041B2 (en) 2013-03-05 Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261606663P 2012-03-05 2012-03-05
PCT/US2013/029171 WO2013134295A1 (en) 2012-03-05 2013-03-05 Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Publications (1)

Publication Number Publication Date
NZ629843A true NZ629843A (en) 2017-03-31

Family

ID=47892055

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ629843A NZ629843A (en) 2012-03-05 2013-03-05 Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Country Status (16)

Country Link
US (3) US10947281B2 (enExample)
EP (1) EP2822964B1 (enExample)
JP (3) JP6395611B2 (enExample)
KR (1) KR102137717B1 (enExample)
CN (2) CN111378020A (enExample)
AU (4) AU2013230112A1 (enExample)
CA (1) CA2866405A1 (enExample)
DK (1) DK2822964T3 (enExample)
EA (1) EA201491643A1 (enExample)
ES (1) ES2703324T3 (enExample)
HU (1) HUE040487T2 (enExample)
MX (1) MX360085B (enExample)
NZ (1) NZ629843A (enExample)
PL (1) PL2822964T3 (enExample)
PT (1) PT2822964T (enExample)
WO (1) WO2013134295A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470790B2 (en) 2006-05-04 2013-06-25 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
US9453241B2 (en) 2010-05-04 2016-09-27 Wayne State University AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
CN111378020A (zh) 2012-03-05 2020-07-07 韦恩州立大学 通道视蛋白-2(Chop2)突变的鉴定及使用方法
WO2014160281A2 (en) 2013-03-14 2014-10-02 Wayne State University Method of enhancing delivery of therapeutic compounds to the eye
US10234761B2 (en) 2013-07-08 2019-03-19 Basf Se Oxime ester photoinitiators
WO2015138616A1 (en) 2014-03-11 2015-09-17 Wayne State University A modified mglur6 promoter and methods of use
KR20230160967A (ko) 2016-05-03 2023-11-24 웨인 스테이트 유니버시티 프로테오좀 억제제를 사용하여 눈에서 바이러스 매개 유전자 전달을 향상시키는 방법
JP2019522469A (ja) * 2016-06-03 2019-08-15 マックス−プランク−ゲゼルシャフト ツア フェルデルンク デア ヴィッセンシャフテン エー.ファウ. チャネルロドプシンの変異型光誘導性イオンチャネル
RU2019109021A (ru) * 2016-08-29 2020-09-29 Уэйн Стейт Юниверсити Идентификация мутаций в вариантах каналопсина, имеющих улучшенную чувствительность к свету, и способы их применения
WO2018106369A2 (en) * 2016-11-06 2018-06-14 Nanoscope Technologies Llc Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof
WO2018189247A1 (en) * 2017-04-12 2018-10-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. New optogenetic tool
SG11202004940VA (en) * 2017-12-04 2020-06-29 Salvat Lab Sa Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
JP6567153B1 (ja) * 2018-09-28 2019-08-28 学校法人東北工業大学 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム
WO2024226667A2 (en) * 2023-04-24 2024-10-31 Nanoscope Therapeutics Inc. Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4498919A (en) 1983-10-31 1985-02-12 Corning Glass Works Method for making colored photochromic prescription ophthalmic lenses
US6610287B1 (en) 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
EP0977880A2 (en) 1997-04-21 2000-02-09 University Of Florida Materials and methods for treatment of retinal diseases
WO2000015822A1 (en) 1998-09-17 2000-03-23 University Of Florida Methods for treatment of degenerative retinal diseases
CA2406743A1 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
EP1381276A4 (en) 2001-04-13 2005-02-02 Univ Pennsylvania METHOD FOR TREATMENT OR DEVELOPMENT SLUDGE DEGRADATION
WO2003016486A2 (en) 2001-08-16 2003-02-27 Sloan Kettering Institute For Cancer Research Bio-synthetic photostimulators and methods of use
DE10216005A1 (de) 2002-04-11 2003-10-30 Max Planck Gesellschaft Verwendung von biologischen Photorezeptoren als direkt lichtgesteuerte Ionenkanäle
WO2004009022A2 (en) 2002-07-18 2004-01-29 The General Hospital Corp. Method for augmenting vision in persons suffering from photoreceptor cell degeneration
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
JP2007527738A (ja) 2003-11-05 2007-10-04 ニューロヴィジョン, インコーポレイテッド 視覚を改善するための方法および装置
US20070053996A1 (en) 2005-07-22 2007-03-08 Boyden Edward S Light-activated cation channel and uses thereof
US8470790B2 (en) * 2006-05-04 2013-06-25 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
US9453241B2 (en) 2010-05-04 2016-09-27 Wayne State University AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
SI2614079T1 (sl) * 2010-09-08 2015-10-30 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Mutantski kanalnirodopsin 2
CN111378020A (zh) * 2012-03-05 2020-07-07 韦恩州立大学 通道视蛋白-2(Chop2)突变的鉴定及使用方法
KR101639859B1 (ko) * 2014-03-06 2016-07-14 포항공과대학교 산학협력단 광 자극에 의한 미토콘드리아 활성의 시공간적 가역 조절 방법

Also Published As

Publication number Publication date
HK1205744A1 (en) 2015-12-24
EA201491643A1 (ru) 2015-02-27
HUE040487T2 (hu) 2019-03-28
PL2822964T3 (pl) 2019-05-31
CA2866405A1 (en) 2013-09-12
AU2021245195B2 (en) 2023-09-28
KR102137717B1 (ko) 2020-07-27
JP2019193656A (ja) 2019-11-07
AU2017239601B2 (en) 2019-05-16
NZ727041A (en) 2022-01-28
MX2014010664A (es) 2015-03-06
AU2017239601A1 (en) 2017-10-26
EP2822964B1 (en) 2018-08-22
CN104334575A (zh) 2015-02-04
AU2013230112A1 (en) 2014-09-25
CN111378020A (zh) 2020-07-07
US20150044181A1 (en) 2015-02-12
AU2021245195A1 (en) 2021-11-04
WO2013134295A1 (en) 2013-09-12
US10947281B2 (en) 2021-03-16
DK2822964T3 (en) 2018-12-10
EP2822964A1 (en) 2015-01-14
ES2703324T3 (es) 2019-03-08
US20220033449A1 (en) 2022-02-03
JP2015510759A (ja) 2015-04-13
KR20140132401A (ko) 2014-11-17
MX360085B (es) 2018-10-10
JP6395611B2 (ja) 2018-09-26
JP2018134098A (ja) 2018-08-30
PT2822964T (pt) 2018-11-29
AU2019216638B2 (en) 2021-07-08
US20250066431A1 (en) 2025-02-27
AU2019216638A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
IN2014CN04498A (enExample)
PH12013500715A1 (en) Anticancer fusion protein
NZ630536A (en) Therapeutic agent or prophylactic agent for dementia
PH12013500714A1 (en) Anticancer fusion protein
MX2014008028A (es) Proteina de fusion anticancerigena.
GB201206559D0 (en) Polypeptide
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
EP4223772A3 (en) Optimized factor viii gene
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
EA201401211A1 (ru) Улучшенные варианты фермента химозина
IN2014DN09963A (enExample)
GB2517354A (en) Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
PH12013501970A1 (en) Anticancer fusion protein
WO2011135222A3 (fr) Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
NZ729514A (en) Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
EP3925968A3 (en) Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
EP4461371A3 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
DK201370709A (en) Protein for use as a medicament
GB201019467D0 (en) Therapeutic agent

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 MAR 2020 BY SHELSTON IP PTY LTD

Effective date: 20170808

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2023 BY COMPUTER PACKAGES INC

Effective date: 20220217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2024 BY CPA GLOBAL

Effective date: 20230120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250116